{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:11:32Z","timestamp":1760202692169},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T00:00:00Z","timestamp":1445644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10157-015-1182-3","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T02:54:48Z","timestamp":1445655288000},"page":"469-478","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis"],"prefix":"10.1007","volume":"20","author":[{"name":"BOREAS HD study Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marenao","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Moniwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaneto","family":"Mitsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,24]]},"reference":[{"key":"1182_CR1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/sdi.12195","volume":"27","author":"T Shafi","year":"2014","unstructured":"Shafi T, Waheed S, Zager PG. Hypertension in hemodialysis patients: an opinion-based update. Semin Dial. 2014;27:146\u201353.","journal-title":"Semin Dial"},{"key":"1182_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1744-9987.2007.00479.x","volume":"11","author":"K Iseki","year":"2007","unstructured":"Iseki K, Nkai S, Shinzato T, et al. Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. Ther Apher Dial. 2007;11:183\u20138.","journal-title":"Ther Apher Dial"},{"key":"1182_CR3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(03)00366-8","volume":"115","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291\u20137.","journal-title":"Am J Med"},{"key":"1182_CR4","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/j.1523-1755.2004.00569.x","volume":"65","author":"A Argil\u00e9s","year":"2004","unstructured":"Argil\u00e9s A, Lorho R, Servel MF, et al. Seasonal modifications in blood pressure are mainly related to interdialytic body weight gain in dialysis patients. Kidney Int. 2004;65:1795\u2013801.","journal-title":"Kidney Int"},{"doi-asserted-by":"crossref","unstructured":"K\/DOQI Workgroup. K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45: S1-S153.","key":"1182_CR5","DOI":"10.1053\/j.ajkd.2005.01.019"},{"key":"1182_CR6","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/ndt\/gfs094","volume":"27","author":"B Canaud","year":"2012","unstructured":"Canaud B, Lertdumrongluk P. Probing \u2018dry weight\u2019 in haemodiaysis patients: \u2018back to the future\u2019. Nephrol Dial Transplant. 2012;27:2140\u20133.","journal-title":"Nephrol Dial Transplant"},{"key":"1182_CR7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/1744-9987.12017","volume":"17","author":"T Ishimitsu","year":"2013","unstructured":"Ishimitsu T, Ohta S, Takahashi T, et al. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients. Ther Apher Dial. 2013;17:524\u201331.","journal-title":"Ther Apher Dial"},{"key":"1182_CR8","first-page":"16","volume":"5","author":"WC Mello De","year":"2014","unstructured":"De Mello WC, Frohlich ED. Clinical perspectives and fundamental aspects of local cardiovascular and renal renin-angiotensin system. Front Endocrinol. 2014;5:16.","journal-title":"Front Endocrinol"},{"key":"1182_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e318249d387","volume":"345","author":"LY Yang","year":"2013","unstructured":"Yang LY, Ge X, Wang YL, et al. Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta analysis. Am J Med Sci. 2013;345:1\u20139.","journal-title":"Am J Med Sci"},{"key":"1182_CR10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11906-010-0137-z","volume":"12","author":"AD Sinha","year":"2010","unstructured":"Sinha AD, Agarwal R. Should all hypertensive dialysis patients receive a blocker of the Renin-Angiotensin system? Curr Hypertens Rep. 2010;12:356\u201363.","journal-title":"Curr Hypertens Rep"},{"key":"1182_CR11","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","volume":"32","author":"PC Austin","year":"2013","unstructured":"Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32:2837\u201349.","journal-title":"Stat Med"},{"key":"1182_CR12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/1077558710361486","volume":"67","author":"Z Luo","year":"2010","unstructured":"Luo Z, Gardiner JC, Bradley CJ. Applying propensity socore methods in medical research: pittfalls and prospects. Med Care Res Rev. 2010;67:528\u201354.","journal-title":"Med Care Res Rev"},{"key":"1182_CR13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB. Reducing bias in obsevational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516\u201324.","journal-title":"J Am Stat Assoc"},{"key":"1182_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum PR, Rubin DB. Constructing a control group using multivariate mathed sampling methods that incorporate the propensity score. Am Stat. 1985;39:33\u20138.","journal-title":"Am Stat"},{"key":"1182_CR15","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/eurjhf\/hft082","volume":"15","author":"CH Tang","year":"2013","unstructured":"Tang CH, Chen TH, Whang CC, et al. Renin-angiotensin system blokade in heart failure patients on long-term haemodialysis in Taiwan. Eur J Heart Fail. 2013;15:1194\u2013202.","journal-title":"Eur J Heart Fail"},{"key":"1182_CR16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ki.2011.228","volume":"80","author":"KE Chan","year":"2011","unstructured":"Chan KE, Ikizler TA, Gamboa JL, et al. Combied angiotensin-coverting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int. 2011;80:978\u201385.","journal-title":"Kidney Int"},{"key":"1182_CR17","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/MD.0000000000000424","volume":"94","author":"CK Wu","year":"2015","unstructured":"Wu CK, Yang YH, Juang JM, et al. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis. Medicine. 2015;94:e424.","journal-title":"Medicine"},{"key":"1182_CR18","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","volume":"21","author":"A Takahashi","year":"2006","unstructured":"Takahashi A, Takase H, Toriyama T, et al. Candesartan, a angiotensin II type-1 receptor, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant. 2006;21:2507\u201312.","journal-title":"Nephrol Dial Transplant"},{"key":"1182_CR19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","volume":"52","author":"H Suzuki","year":"2008","unstructured":"Suzuki H, Kannno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemo dialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52:501\u20136.","journal-title":"Am J Kidney Dis"},{"key":"1182_CR20","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","volume":"28","author":"K Iseki","year":"2013","unstructured":"Iseki K, Arima H, Kohagura K,\u00a0et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized control trial. Nephrol Dial Transplent. 2013;28:1579\u201389.","journal-title":"Nephrol Dial Transplent"},{"key":"1182_CR21","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","volume":"70","author":"F Zannad","year":"2006","unstructured":"Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318\u201324.","journal-title":"Kidney Int"},{"key":"1182_CR22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ki.2014.69","volume":"86","author":"CD Peters","year":"2014","unstructured":"Peters CD, Kjaergaard KD, Jensen JD, et al. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end point in hemodialysis patients. Kidney Int. 2014;86:625\u201337.","journal-title":"Kidney Int"},{"key":"1182_CR23","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1046\/j.1523-1755.2002.00355.x","volume":"61","author":"B Kestenbaum","year":"2002","unstructured":"Kestenbaum B, Gillen DL, Sherrard DJ, et al. Calcium channel blocker use and mortality amoung patients with end-stage renal disease. Kidney Int. 2002;61:2157\u201364.","journal-title":"Kidney Int"},{"key":"1182_CR24","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","volume":"23","author":"M Tepel","year":"2008","unstructured":"Tepel M, Hopfenmueller W, Scholze A, et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplent. 2008;23:3605\u201312.","journal-title":"Nephrol Dial Transplent"},{"key":"1182_CR25","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","volume":"373","author":"HJ Heerspink","year":"2009","unstructured":"Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patientson dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373:1009\u201315.","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-015-1182-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1182-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T23:41:54Z","timestamp":1718149314000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-015-1182-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,24]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1007\/s10157-015-1182-3","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2015,10,24]]}}}